Clario announces investment in new translation services technology to accelerate eCOA study start-up and improve patient access to clinical trials globally | newsletter

Leading provider of endpoint technologies for clinical trials sets ambitious targets to reduce translation time by 20-30% by investing in new technologies and processes

PhiladelphiaAnd the 13. August 2022 /PRNewswire/- ClarioToday, a technology company that provides leading endpoint technology solutions for decentralized, hybrid and on-premise clinical trials (DCT), announced an investment in a new translation services technology – Clario Translation Workbench – that accelerates translation times. by 20-30% It should be shortened. This will reduce times for ramping up eCOA studies and improve patients’ access to clinical trials worldwide.

“Our clients need to run studies in multiple countries and ensure that patients receive accurate and timely translations to evaluate their own electronic clinical outcomes. This is critical to a successful study. With Clario’s global reach and this investment in technology and processes to reduce translation times, we can help in improving patient access and overall study preparation times,” Andy CooperEVP eCOA and Enabling Experience.

translation table:

• Use new technologies to reduce the time spent communicating between a translation provider and Clario
• Reduce the tedious processes associated with taking accurate screenshots and translating appropriate screens in eCOA applications
• Reduce defects and reduce human error by investing in automation and a new data-centric platform

Clients need reliable translation services to conduct studies in multiple countries and reach a diverse group of patients. However, they often encounter delays and technical issues. The main focus of the investment is to reduce the number of manual steps that are often required in the technical and complex process of producing accurate translations. Clario’s new translation workbench technology has been developed and released to directly address these issues.

About Clario

For nearly 50 years, delivery has been Clario Leading technology solutions for clinical trials. With experience gained from more than 19,000 clinical trials that have supported 870 regulatory accreditations, Clario brings together scientific expertise and global scope in the most comprehensive endpoint technology platform that empowers partners in the pharmaceutical, biotechnology and medical device industries to transform lives. Clario’s Trial Anywhere™ Solutions It has supported decentralized, hybrid clinical trials (DCT) for more than 15 years, enabling sponsors to collect high-quality endpoint data from any modality or site while improving patient experience. Clario has 30 locations in nine countries in North America, Europe, and Asia Pacific.

Logo – https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg